29 research outputs found
Classification probabilities (standard errors) for p53 genotype by two additional laboratory tests, according to true p53 status: results from Model 1 with extended dataset.
*<p>Boundary solution: estimated values of zero for probability and its standard error.</p
Cross tabulation of genotyping test results across four laboratory methods and by cytology status.
<p>Cross tabulation of genotyping test results across four laboratory methods and by cytology status.</p
Pairwise comparison of agreement among laboratory methods using crude agreement percentages and kappa coefficients.
<p>Pairwise comparison of agreement among laboratory methods using crude agreement percentages and kappa coefficients.</p
Prevalence (standard error) of p53 genotypes in case and non-case groups, and empirical ORs, for four laboratory tests.
<p>Prevalence (standard error) of p53 genotypes in case and non-case groups, and empirical ORs, for four laboratory tests.</p
Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination
<div><p>Background</p><p>Millions of women have been vaccinated with one of two first-generation human papillomavirus (HPV) vaccines. Both vaccines remain in use and target two oncogenic types (HPVs 16 and 18); however, if these types naturally compete with others that are not targeted, type replacement may occur following reductions in the circulating prevalence of targeted types. To explore the potential for type replacement, we evaluated natural HPV type competition in unvaccinated females.</p><p>Methods</p><p>Valid HPV DNA typing information was available from five epidemiological studies conducted in Canada and Brazil (n = 14,685; enrollment across studies took place between1993 and 2010), which used similar consensus-primer PCR assays, capable of detecting up to 40 HPV types. A total of 38,088 cervicovaginal specimens were available for inclusion in our analyses evaluating HPV type-type interactions involving vaccine-targeted types (6, 11, 16, and 18), and infection with each of the other HPV types.</p><p>Results</p><p>Across the studies, the average age of participants ranged from 21.0 to 43.7 years. HPV16 was the most common type (prevalence range: 1.0% to 13.8%), and in general HPV types were more likely to be detected as part of a multiple infection than as single infections. In our analyses focusing on each of the vaccine-targeted HPV types separately, many significant positive associations were observed (particularly involving HPV16); however, we did not observe any statistically significant negative associations.</p><p>Conclusions</p><p>Our findings suggest that natural HPV type competition does not exist, and that type replacement is unlikely to occur in vaccinated populations.</p></div
Grouped and type-specific seroprevalence of 9vHPV types among men from Brazil, Mexico and the United States
<p>Grouped and type-specific seroprevalence of 9vHPV types among men from Brazil, Mexico and the United States</p
Characteristics of female participants at baseline/enrollment in five epidemiological studies.
<p>Characteristics of female participants at baseline/enrollment in five epidemiological studies.</p
Association between demographic, lifestyle and sexual behavior factors and external genital lesions (EGLs) and controls.
<p>Association between demographic, lifestyle and sexual behavior factors and external genital lesions (EGLs) and controls.</p
Participant characteristics by seropositivity to high-risk and low-risk types in 9vHPV vaccine.
<p>Participant characteristics by seropositivity to high-risk and low-risk types in 9vHPV vaccine.</p
Type-specific seroprevalence of nine HPV vaccine types by age group.
<p>Significant p-value <0.05 is marked with â*â. P-value was obtained from Cochran-Armitage Trend Test. P<sub>trend</sub> <0.05 for HPV types 18, 45 and 58.</p